TD Cowen Reiterates Buy Rating on Exelixis (EXEL)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Leerink Partners Reiterates Market Perform Rating on Exelixis (EXEL)
October 16, 2024 6:54 AM EDTLeerink Partners analyst Christopher Liu reiterated a Market Perform rating and $28.50 price target on Exelixis (NASDAQ: EXEL)
The analyst comments "Bottom Line: The long-awaited decision (here) in the patent infringement trial vs MSN (private) on Cabometyx was issued on October 15 intraday, which is a positive development for EXEL. For the malate salt patents comprising '439, '440 and '015 expiring Jan 2030, the Judge found the patents valid. Additionally, the Judge found that Claim 3 of the '349 patent (referring to formulation impurities for cabo, potentially during the manufacturing/synthesis... More
Exelixis (EXEL) PT Raised to $34 at RBC Capital
October 16, 2024 6:50 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Exelixis (NASDAQ: EXEL) to $34.00 (from $30.00) while maintaining a Outperform rating.
The analyst comments "Today's ruling in favor of Cabo's protection into 2030 has, in our view, created a refreshed forward-orienting set-up for shares with... More
Goldman Sachs Reiterates Sell Rating on Exelixis (EXEL)
October 16, 2024 6:03 AM EDTGoldman Sachs analyst Chris Shibutani reiterated a Sell rating and $18.00 price target on Exelixis (NASDAQ: EXEL).
The analyst comments "The US District Court in Delaware ruled in favor of Exelixis in the "MSN II" case rejecting the challenge posed by MSN to three Orange Book-listed patents relating to EXEL's cabozantinib, assuring protection from generic entry... More
